These 4 companies reported earnings on a rocky Monday. Will this 4 companies pave the wave for a better week?
1) Texas Instruments (NYSE:TXN): After the closing bell, the company released Q1 earnings. EPS of 55 cents missed analysts estimates by 3 cents. Revenue increased 6% from last year in the same period to $3.4 billion. The chip maker blamed Japan for its problems, as it tries to restart operations after the 8.9 magnitude earthquake. Shares traded down 1.5% after the disappointing earnings release. Competitor Qualcomm (NASDAQ:QCOM) also fell in late trading, and smaller rival STMicroelectronics (NYSE:STM) closed down 3.69%.
2) Citigroup (NYSE:C): Shares were flat after the company reported Q1 earnings. The third largest bank in the country reported net earnings of $3 billion (10 cents per share), compared to $4.4 billion (15 cents per share) last year. Revenue also fell 22% from last year to $19.7 billion. Investors should keep an eye on the bank’s reserve releases, which can help boost earnings. Citi released $3.3 billion from reserves for the quarter. Last week, other mega banks such as Bank of America (NYSE:BAC) and JP Morgan (NYSE:JPM) also announced disappointing earnings.
3) TD Ameritrade (NASDAQ:AMTD): The company provides securities brokerage services to retail investors, traders, and independent investment advisors. Before the opening bell, the company reported fiscal Q2 earnings. EPS of 30 cents beat estimates by 1 penny. Compared to last year, revenue increased 9.4% to $718.2 million. The positive results weren’t enough to boost shares though. Shares closed down nearly 2%. Charles Schwab (NYSE:SCHW) had an even worse day as shares closed down over 3%.
4) Eli Lilly (NYSE:LLY): The company develops, manufactures, and sells pharmaceutical products worldwide. Shares currently boast a 5.5% yield, but will Q1 earnings support the dividend? Q1 EPS of $1.24 beat estimates by 8 cents. Revenue grew 6.4% from last year to $5.84 billion. The company has a smaller market cap than rivals GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), but Eli Lilly has a lower P/E ratio. Going forward, patent expirations will be a major pill for the company to swallow in the next two years.
Don’t Miss Wall St. Cheat Sheet’s Dow 30 Quarterly Earnings Season Preview.
Disclosure: No positions